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A B S T R A C T
Background
Delivering the diagnosis of a serious illness is an important skill in most fields of medicine, including mental health. Research has
found that communication skills can impact on a person’s recall and understanding of the diagnosis, treatment options and prognosis.
People may feel confused and perplexed when information about their illness is not communicated properly. Sharing information about
diagnosis of a serious mental illness is particularly challenging. The nature of mental illness is often difficult to explain since there may
be no clear aetiology, and the treatment options and prognosis may vary enormously. In addition, newly diagnosed psychiatric patients,
who are actively ill, often may not accept their diagnosis due to lack of insight or stigma attached to the condition. There are several
interventions that aim to help clinicians to communicate life changing medical diagnoses to people; however, little is known specifically
for delivering a diagnosis of schizophrenia.
Objectives
To evaluate evidence from randomised controlled trials (RCTs) for the efficacy of different communication strategies used by clinicians
to inform people about the diagnosis and outcome of schizophrenia compared with treatment as usual and to compare efficacy between
different communication strategies.
Search methods
On 22 June 2015 and 29 June 2016, we searched the Cochrane Schizophrenia Group’s Study-Based Register of Trials. We also searched
sources of grey literature (e.g., dissertations, theses, clinical reports, evaluations published on websites, clinical guidelines and reports
from regulatory agencies).
Selection criteria
We planned to include all relevant RCTs that included adults with schizophrenia or related disorders, including schizophreniform
disorder, schizoaffective disorder and delusional disorder. The trials would have investigated the effects of communication strategy or
strategies that helped clinicians deliver information specifically about a diagnosis of schizophrenia (which can also include communi-
cation regarding the treatment options available and prognosis).
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Data collection and analysis
Review authors independently examined all reports from the searches for any relevant studies. We planned to extract data independently.
For binary outcomes, we would have calculated risk ratio (RR) and its 95% confidence interval (CI), on an intention-to-treat basis.
For continuous data, we would have estimated the mean difference (MD) between groups and its 95% CI. We would have employed
a random-effects model for analyses. We planned to assess risk of bias for included studies. We created a ’Summary of findings’ table
using GRADE.
Main results
The searches identified 44 records which appeared to be relevant to the aims of the review. We obtained full reports for seven potential
studies; however, after close inspection none of these studies met the inclusion criteria.
Authors’ conclusions
Good communication of diagnosis can affect treatment planning, compliance and patient outcomes, especially in the case of conditions
such as schizophrenia, which has the potential to cause serious life disruption for both people with schizophrenia and their carers.
Currently, there is no evidence based on findings fromRCTs assessing the effects of communication strategies for disclosing the diagnosis
of schizophrenia and related disorders. Research is required.
P L A I N L A N G U A G E S U M M A R Y
Sharing information about the diagnosis and outcomes of schizophrenia: evidence from well-designed clinical trials
Background
Health professionals have a duty to give information to their patients in a way that is understandable, especially when the condition
is severe and life altering. Schizophrenia and similar related disorders are serious mental illnesses that can have long term, disruptive
effects on the lives of both patients and their carers. The way a person is told they have a serious illness and what having this illness
will mean for them can affect how they accept their diagnosis and treatment plans which then ultimately can affect their recovery and
long-term outlook. At the moment, there is no information or evidence regarding how best to disclose a diagnosis of schizophrenia.
Searching for evidence
In June 2015 and June 2016, we explored the medical literature and the Cochrane Schizophrenia Group’s study-based register using
appropriate keywords to find any studies which evaluated a method that guided or helped health professionals with how to deliver the
news about the diagnosis of schizophrenia. We specifically searched for randomised controlled trials as these are considered the best
way (gold standard) to evaluate the effects of treatments. We identified 44 publications and inspected these. From these, we obtained
seven full reports of trials and that we thought could be relevant; however, none of these studies could be included in the review.
Conclusions
Currently health professionals can use good quality, evidence based information to guide them in the sharing of news about diagnosis
of a serious physical illnesses; however, there is no such evidence available concerning the sharing of news about the diagnosis of
schizophrenia. This is a serious gap in knowledge which needs attention and studies are needed in this area.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Communication strategies for compared with treatment as usual for disclosing a diagnosis of schizophrenia or related disorders
Patient or population: people with schizophrenia and their carers
Settings: hospital or community
Intervention: communicat ion strategy to impart information about diagnosis of schizophrenia
Comparison: t reatment as usual
Outcomes No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Engagement with services: clinically im-
portant change in engagement with ser-
vices, as def ined by individual studies
- - No evidence f rom randomised trials.
Treatment adherence: clinically important
change in treatment adherence, as def ined
by individual studies
- -
Understanding:
clinically important change in understand-
ing the nature of illness and its outcome,
as def ined by individual studies
- -
Quality of life: clinically important change
in general quality of lif e or well-being, as
def ined by individual studies
- -
Mental state: clinically important change
in mental state, as def ined by individual
studies
- -
Satisfaction communication of diagno-
sis: clinically important change (pat ient or
carer’s), as def ined by individual studies
- -
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Adverse effect: clinically important ad-
verse ef fect of intervent ion - as def ined by
individual studies
- -
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
Schizophrenia and related disorders are a group of serious men-
tal illnesses typically characterised by the presence of delusions,
hallucinations, disorganised speech, disorganised behaviour and
negative symptoms (avolition, apathy, anhedonia, alogia, affective
blunting). Schizophrenia typically presents formales in early adult-
hood or late adolescence (for females the age of onset is slightly
later) and affects around 0.30% to 0.66% of people at some point
in their life (McGrath 2008). Schizophrenia impairs quality of life
and severely impacts the ability of a person to live andwork (Krupa
2004).
Diagnosing schizophrenia is not straightforward. The validity of
the concept and even the term schizophrenia is fiercely debated
and it can be profoundly stigmatising (Lieberman 2007). Most
early intervention andprodromal services prefer the termpsychosis
instead of schizophrenia, although the effects of using the term
psychosis or any other alternative to schizophrenia is also currently
not evidence based. The two major classification systems, the Di-
agnostic and Statistical Manual of Mental Disorders (DSM) and
International Classification of Diseases (ICD-10), have different
requirements of symptomduration for the diagnosis of schizophre-
nia. While the DSM requires presence of symptoms for a mini-
mum of six months, the ICD-10 warrants a minimum duration
of one month. The DSM-IV has a requirement for social/occupa-
tional dysfunction; the ICD-10 had no such requisite (APA 2013).
Once diagnosed, delivering the diagnosis and sharing information
about the treatment options and prognosis of schizophrenia with
the person can be very challenging for clinicians. The nature of the
condition is often difficult to explain since there is no clear aetiol-
ogy and outcome is variable. Unlike most physical illnesses, people
may not accept a mental health diagnosis due to lack of insight or
stigma. Feelings of alienation, devaluation by others, worry about
being viewed unfavourably and avoidance of self-disclosure about
mental illness are among the most common reported stigma ex-
periences for people with schizophrenia (Dickerson 2002).
Description of the intervention
A communication strategy is defined as any intervention aimed at
improving communication between mental health professionals
and patients or carers, or both. Effective medical communication
strategies take into account the nature and stage of illness, a person’s
view of the illness, their help-seeking behaviour and their prior
knowledge.
A number of different models for breaking bad news regarding
health have been published in other branches of medicine. The
most commonly reportedmodel is SPIKES (Buckman 1992). This
model has six steps for breaking news of a serious diagnosis: 1.
start off well, 2. find out how much the patient/family knows, 3.
find out how much the patient/family want to know, 4. share the
information, 5. respond to patient’s/family feelings and 6. plan and
follow through (Buckman 1992). These steps have been modified
for different conditions, including, in mental health, dementia
(Carpenter 2004) and learning disability (Tuffrey-Wijne 2013),
but not specifically for schizophrenia. Seeman 2010 suggested that
the SPIKES model could be applied to schizophrenia; however,
this suggestion is based on qualitative information.
It should be noted that the communication strategy we are dis-
cussing here is different to general communication skills between
clinicians and patients. These communication skills are related to
discussions of the condtions and treatment options for that and
is the focus of another Cochrane Review (Papageorgiou 2017).
Similarly psychoeducation which is designed to inform and help
people learn about their illness is also covered by another review
(Xia 2011). The intervention for this review is a strategy or set of
communication strategies specifically for delivery of the diagnosis
and outcome of schizophrenia.
How the intervention might work
The diagnosis of a severe mental illness such as schizophrenia can
cause anxiety and despair when delivered without consideration
of the person’s views about mental illness and the potential ef-
fects of the diagnosis on their mental health. Carers can also be
affected by receiving such news. Good initial delivery of informa-
tion about having a severe mental illness aids informed decision-
making about treatment and empowers people and their families.
Such interventions in the form of different communication strate-
gies can help to reduce anxiety, fear and stigma. They may help to
foster better engagement with mental health services, which can
lead to better compliance with treatment.
Why it is important to do this review
Doctors have a duty to provide information to people in a way
that is understandable to them (General Medical Council 2009).
Delivering information about a serious diagnosis or life-threaten-
ing outcomes is an important skill in most fields of medicine, such
as oncology, paediatrics and obstetrics (Fallowfield 2004). Given
the plethora of research in other medical disciplines, it is surpris-
ing that in psychiatry, research on communicating information
about a serious illness is mostly limited to dementia (Cleary 2009;
Mitchell 2007).
The National Institute for Health and Care Excellence (NICE)
guidelines recommend that information about the causes and
treatment options for schizophrenia be discussed with the patient
and their carers, but does not offer advice on how to commu-
nicate to a person the news that he or she has been diagnosed
with schizophrenia (NICE 2009). Currently there is no clear strat-
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egy available and people with schizophrenia have varied experi-
ences. One literature review on disclosure of mental health di-
agnosis found that of service users with schizophrenia, 45% re-
ceived no information regarding their diagnosis compared to a
mean of 20% for other mental health diagnoses. There were simi-
lar findings in psychiatrist surveys (Clafferty 2001; Luderer 1993;
McDonald-Scott 1992; Shergill 1998), except when episodes were
recurrent (Clafferty 2001). McDonald-Scott found providing a
substitute diagnosis in place of a schizophrenia diagnosis is re-
ported as common practice, and this remained the case even
when exact diagnostic information was sought by service-users
(McDonald-Scott 1992).
In a multicultural society, cross-cultural issues can pose an-
other challenge. One cross-cultural study revealed that 30% of
North Americans and more than 70% of Japanese psychiatrists
would not inform people about their diagnosis of schizophrenia
(McDonald-Scott 1992). In addition, there are some Chinese-
American psychiatrists who believe that not disclosing a diagno-
sis of schizophrenia to be one of the most effective treatment ap-
proaches when working with Chinese-American people (Hwang
2008).
Psychiatric literature on sharing news about serious mental illness
is, at the moment, mostly limited to questionnaire-based surveys
of psychiatrist and other mental health professionals about their
practice (Clafferty 2001; Cleary 2009; Green 1984; Marzanski
2000; Üçok 2004), family members (Lauber 2003), and semi-
structured interviews with patients (Gallagher 2010).
Therefore, we feel it is important to evaluate the available evidence
and determine if more research is needed. The present review
aims to help to identify available interventions and evaluate their
effectiveness. This will assist in providing an evidence base and
developing guidelines for best practice in this area. It can also
identify gaps in the knowledge so we can gather information that
leads to better design and implementation of future randomised
controlled trials (RCT).
O B J E C T I V E S
To evaluate evidence from randomised controlled trials (RCTs)
for the efficacy of different communication strategies used by
clinicians to inform people about the diagnosis and outcome of
schizophrenia compared with treatment as usual and to compare
efficacy between different communication strategies.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All relevant RCTs. If a trial was described as ’double blind’ but
implied randomisation, we would have included such trials in a
sensitivity analysis (see Sensitivity analysis). We would have ex-
cluded quasi-randomised studies, such as those allocating by al-
ternate days of the week. Where participants are given additional
interventions within an information-sharing strategy, we would
only have included data if the adjunct treatment was evenly dis-
tributed between groups and only the information-sharing strat-
egy was randomised.
Types of participants
Adults and adolescents (agedmore than 16 years) however defined,
with schizophrenia or related disorders, including schizophreni-
form disorder, schizoaffective disorder and delusional disorder, by
any means of diagnosis. The communication strategies may also
have involved carers and relatives. Communication strategies in-
volving relatives would have needed to be described as such. We
would have reported outcomes about carers separately. We would
have only included trials where over 50% of the participants had
schizophrenia.
To ensure that information was as relevant to the current care of
people with schizophrenia we planned to clearly highlight the cur-
rent clinical state (acute, early postacute, partial remission, remis-
sion) and the stage (prodromal, first episode, early illness, persis-
tent) and as to whether the studies primarily focused on people
with particular problems (e.g. subtypes of schizophrenia).
Types of interventions
1. Communication strategies
Information-sharing strategies designed to help clinicians commu-
nicate the diagnosis of schizophrenia to people with schizophrenia
and their carers.
We defined these as any intervention aimed at improving com-
munication between mental health professionals and patients or
carers, or both about the diagnosis of schizophrenia. This commu-
nication could also have involved discussion regarding treatment
options and prognosis.
We hypothesised that a communication strategy should address
the following areas:
1. when to communicate the diagnosis;
2. what information should (and should not) be
communicated;
3. how to communicate this information.
Communication strategies may have included different compo-
nents such as cultural, medical, legal and ethical considerations.
They may also have included communication with carers or with
patients who may have limited or no insight into their condition.
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2. Treatment as usual
The controls may have included no particular strategy (usually
described as treatment as usual)
We aimed, if possible, to also compare different communication
strategies with each other.
Types of outcome measures
We planned to divide all outcomes into short term (less than six
months), medium term (six to 12 months) and long term (over
one year). Primary outcomes were engagement with services and
treatment adherence.We also aimed to evaluate strategies in terms
of improvement in understanding the nature of the illness and its
outcome, psychopathology, disability and satisfaction with health
care.We would have only used scale data measured using validated
scales (see Data extraction and management).
Primary outcomes
1. Engagement with services
1.1. Clinically important change in engagement with services, as
defined by individual studies.
2. Treatment adherence
2.1. Clinically important change in treatment adherence, as de-
fined by individual studies.
Secondary outcomes
1. Engagement with services
1.1. Any change in engagement with services, as defined by indi-
vidual studies.
2. Treatment adherence
2.1. Any change in treatment adherence, as defined by individual
studies.
3. Understanding
3.1. Clinically important change in understanding the nature of
illness and its outcome, as defined by individual studies.
3.2. Any change in understanding the nature of illness and its
outcome, as defined by individual studies.
3.3. Change in insight.
3.4. Change in patients’ beliefs about illness.
4. Quality of life or well-being
4.1. Clinically important change in general quality of life or well-
being, as defined by individual studies.
4.2. Any change in quality of life or well-being, as defined by
individual studies.
4.3. Mean endpoint/change score in general quality of life score
or well-being scales.
5. Mental state
5.1. Clinically important change in mental state, as defined by
individual studies.
5.2. Any change in mental state, as defined by individual studies.
5.3. Mean endpoint/change score in mental state scales.
6. General functioning
6.1. Clinically important change in general functioning, as defined
by individual studies.
6.2. Any change in general functioning, as defined by individual
studies.
6.3. Mean endpoint/change score on general functioning scales.
7. Behaviour
7.1. Clinically important change in behaviour (e.g. self-harm), as
defined by individual studies.
7.2. Any change in behaviour, as defined by individual studies.
7.3. Mean endpoint/change score behaviour scales.
8. Satisfaction with communication of diagnosis
8.1. Clinically important change in patient satisfaction, as defined
by individual studies.
8.2. Clinically important change in carer satisfaction, as defined
by individual studies.
8.3. Clinically important change in health professional satisfac-
tion, as defined by individual studies.
8.4. Mean endpoint/change score on satisfaction scales.
8.5. Leaving the study early.
9. Adverse effects from disclosure of diagnosis for patient or
carers
9.1. Clinically important adverse effect, as defined by individual
studies.
10. Economic
10.1. Direct costs.
10.2. Indirect costs.
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’Summary of findings’ table
We planned to use the GRADE approach to interpret findings
(Schünemann 2011) as well as GRADEpro to import data from
Review Manager 5 to create ’Summary of findings’ tables. These
tables provide outcome-specific information concerning the over-
all quality of evidence from each included study in the compar-
ison, the magnitude of effect of the interventions examined and
the sum of available data on all outcomes we rate as important
to patient-care and decision making. We aimed to select the fol-
lowing main outcomes for inclusion in the ’Summary of findings’
table:
1. engagement with services: clinically important change in
engagement with services, as defined by individual studies;
2. treatment adherence: clinically important change in
treatment adherence, as defined by individual studies;
3. understanding: clinically important change in
understanding the nature of illness and its outcome, as defined
by individual studies;
4. quality of life: clinically important change in general quality
of life or well-being, as defined by individual studies;
5. mental state: clinically important change in mental state, as
defined by individual studies.
6. satisfaction communication of diagnosis: clinically
important change (patient or carer’s), as defined by individual
studies;
7. adverse effects: clinically important adverse effect of
intervention, as defined by individual studies.
In future versions, if data are not available for these prespecified
outcomes but are available for ones that are similar, we will present
the closest outcome to the prespecified one in the table but take
this into account when grading the finding.
Search methods for identification of studies
Electronic searches
Cochrane Schizophrenia Group’s Study-Based Register of
Trials
On 22 June 2015 and 29 June 2016, the information specialist
of the Cochrane Schizophrenia Group searched the register using
the following search strategy:
*Communication* in Intervention Field of STUDY
In such a study-based register, searching the major concept re-
trieves all the synonyms and relevant studies because all the stud-
ies have already been organised based on their interventions and
linked to the relevant topics.
This register is compiled by systematic searches of major resources
(including MEDLINE, Embase, AMED, BIOSIS, CINAHL,
PsycINFO, PubMed and registries of clinical trials) and their
monthly updates, handsearches, grey literature and conference
proceedings (see Group’s Module). There is no language, date,
document type or publication status limitations for inclusion of
records into the register.
For other searches, see Appendix 1.
Searching other resources
1. Reference searching
We would have inspected references of all included studies for
further relevant studies.
2. Personal contact
We would have contacted the first author of each included study
for information regarding unpublished trials.
3. Handsearching
We also searched sources of grey literature (such as dissertations
and theses, clinical reports, evaluations published onwebsites, clin-
ical guidelines and reports from regulatory agencies).
Data collection and analysis
Selection of studies
Two review authors (FNandRJ) independently inspected citations
from the searches to identify relevant abstracts. A third review
author (SF) independently re-inspected a random 20% sample to
ensure reliability. If disputes had occurred, wewould have acquired
the full report for more detailed scrutiny.
Data extraction and management
1. Extraction
Two review authors (FN and SF) would have extracted data from
all included studies. To ensure reliability, RJ would have inde-
pendently extracted data from a random sample of these stud-
ies, comprising 10% of the total. Any disagreement would have
been discussed, decisions documented and, if necessary, authors of
studies contacted for clarification. We would have extracted data
presented only in graphs and figures wherever possible, but in-
clude only if two review authors independently reached the same
conclusion. Where necessary to obtain missing information or for
clarification, we would have attempted to contact authors through
an open-ended request. If studies had been multicentre, we would
have extracted data relevant to each component centre separately
where possible.
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2. Management
2.1. Forms
Wewouldhave extracted data on to standard data extraction forms.
2.2. Scale-derived data
We would include continuous data from rating scales only if:
1. the psychometric properties of the measuring instrument
had been described in a peer-reviewed journal (Marshall 2000);
2. the measuring instrument had not been written or modified
by one of the trialists for that particular trial and
3. the instrument was a global assessment of an area of
functioning and not subscores which are not, in themselves,
validated or shown to be reliable. However, there are exceptions,
we would have included subscores from mental state scales
measuring positive and negative symptoms of schizophrenia.
Ideally the measuring instrument should have been either be a
self-report or completed by an independent rater or relative (not
the therapist). We realise that this is not often reported clearly; in
’Description of studies’ we would have noted if this is the case or
not.
2.3. Endpoint versus change data
There are advantages of both endpoint and change data: change
data can remove a component of between-person variability from
the analysis; however, calculation of change needs two assessments
(baseline and endpoint) that can be difficult to obtain in unsta-
ble and difficult-to-measure conditions such as schizophrenia. We
decided primarily to use endpoint data, and only use change data
if endpoint were not available. If necessary, we would have com-
bined endpoint and change data in the analysis, as we prefer to
use mean differences (MDs) rather than standardised mean dif-
ferences (SMDs) throughout (Deeks 2011).
2.4. Skewed data
Continuous data on clinical and social outcomes are often not
normally distributed. To avoid the pitfall of applying parametric
tests to non-parametric data, we would have applied the following
standards to relevant continuous data before inclusion.
For endpoint data from studies including fewer than 200 partici-
pants:
1. when a scale starts from the finite number zero, we would
have subtracted the lowest possible value from the mean, and
divided this by the standard deviation (SD). If this value was
lower than one, it would strongly suggest that the data were
skewed and we would have excluded these data. If this ratio was
higher than one but less than two, there would have been
suggestion that the data were skewed: we would have entered
these data and tested whether their inclusion or exclusion would
have changed the results substantially. If such data changed
results, we would have entered them as ’other data.’ Finally, if the
ratio was larger than two we would have included these data,
because it was less likely that they were skewed (Altman 1996;
Higgins 2011a);
2. if a scale started from a positive value (such as the Positive
and Negative Syndrome Scale (PANSS), which can have values
from 30 to 210 (Kay 1986)), we would have modified the
calculation described above to take the scale starting point into
account. In these cases, skewed data were present if 2 SD > (S -
Smin), where S was the mean score and Smin was the minimum
score.
Note: we would have entered all relevant data from studies of
more than 200 participants in the analysis irrespective of the above
rules, because skewed data pose less of a problem in large studies.
We would also have entered all relevant change data, as when
continuous data are presented on a scale that includes a possibility
of negative values (such as change data), it is difficult to determine
whether or not data are skewed.
2.5. Common measure
To facilitate comparison between trials, we intended to convert
variables that could have been reported in different metrics, such
as days in hospital (mean days per year, per week or per month)
to a common metric (e.g. mean days per month).
2.6. Conversion of continuous data to binary data
Where possible, we planned to convert continuous outcome mea-
sures to dichotomous data. This can be done by identifying cutoff
points on rating scales and dividing participants accordingly into
’clinically improved’ or ’not clinically improved’ groups. It is gen-
erally assumed that if there is a 50% reduction in a scale-derived
score such as the Brief Psychiatric Rating Scale or the PANSS (Kay
1986; Overall 1962), this could be considered to be a clinically
significant response (Leucht 2005a; Leucht 2005b). If data based
on these thresholds were not available, we would have used the
primary cutoff presented by the original authors.
2.7. Direction of graphs
We intended, where possible, to enter data in such a way that
the area to the left of the line of no effect indicated a favourable
outcome for ’strategies to share the information’ compared to no
strategy or treatment as usual.Where doing thismade it impossible
to avoid outcome titles with clumsy double-negatives (e.g. ’not
unimproved’), we would have reported data where the left of the
line indicated an unfavourable outcome.
Assessment of risk of bias in included studies
Two review authors (SF and ZC) would have worked indepen-
dently to assess risk of bias using criteria described in the Cochrane
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Handbook for Systematic Reviews of Interventions (Higgins 2011b).
This set of criteria is based on evidence of associations between
overestimate of effect and high risk of bias of the article such as se-
quence generation, allocation concealment, blinding, incomplete
outcome data and selective reporting.
If the raters had disagreed, the final rating was to be made by con-
sensus involving all review authors. If details of randomisation and
other characteristics of trials had been inadequate, we would have
contacted authors of the studies to obtain further information. We
would have reported non-concurrence in quality assessment, but
if disputes arose as to which category a trial was to be allocated,
again, we would have resolved them by discussion.
We would have noted the level of risk of bias in both the text of
the review and in the ’Summary of findings’ table.
Measures of treatment effect
1. Binary data
For binary outcomes, we planned to calculate a standard estima-
tion of the risk ratio (RR) and its 95% confidence interval (CI).
It has been shown that RR is more intuitive than odds ratios and
that odds ratios tend to be interpreted as RR by clinicians (Boissel
1999; Deeks 2000). The number needed to treat for an additional
harmful outcome statistic with its CIs is intuitively attractive to
clinicians, but is problematic both in its accurate calculation in
meta-analyses and interpretation (Hutton 2009). Where possible,
for binary data presented in the ’Summary of findings’ table, we
planned to calculate illustrative comparative risks.
2. Continuous data
For continuous outcomes, we planned to estimate the MD be-
tween groups. We prefer not to calculate effect size measures
(SMD). However, if scales of very considerable similarity had been
used, wewould have presumed there was a small difference inmea-
surement, and would have calculated effect size and transform the
effect back to the units of one or more of the specific instruments.
Unit of analysis issues
1. Cluster trials
Studies increasingly employ ’cluster randomisation’ (such as ran-
domisation by a clinician or practice), but analysis and pooling of
clustered data pose problems. First, authors often fail to account
for intraclass correlation in clustered studies, leading to a ’unit of
analysis’ error whereby P values are spuriously low, CIs unduly
narrow and statistical significance overestimated (Divine 1992).
This causes type I errors (Bland 1997; Gulliford 1999).
Where clustering is not accounted for in primary studies, wewould
have presented data in a table with an asterisk symbol to indicate
the presence of a probable unit of analysis error.
We have sought statistical advice and have been advised that the
binary data as presented in a report should be divided by a ’design
effect.’ This is calculated using the mean number of participants
per cluster (m) and the intraclass correlation coefficient (ICC)
(design effect = 1 + (m - 1) × ICC) (Donner 2002). If the ICC
was not reported, we decided to assume it to be 0.1 (Ukoumunne
1999).
2. Cross-over trials
A major concern of cross-over trials is the carry-over effect, which
occurs if an effect (e.g. pharmacological, physiological or psycho-
logical) of the treatment in the first phase is carried over to the
second phase. As a consequence, on entry to the second phase,
the participants can differ systematically from their initial state
despite a washout phase. For the same reason, cross-over trials are
not appropriate if the condition of interest is unstable (Elbourne
2002). As both effects are very likely in severe mental illness, we
would have only used data of the first phase of cross-over studies.
3. Studies with multiple treatment groups
Where a study involvedmore than two treatment arms,we planned
to present the additional treatment arms, if relevant, in compar-
isons. If data were binary, we would have combined these within
the two-by-two table. If data were continuous, we would have
combined data following the formula in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011a).
Dealing with missing data
1. Overall loss of credibility
At a certain degree of loss to follow-up data loses credibility (Xia
2009). We chose that, for any particular outcome, should more
than 50% of data be unaccounted for, we would not reproduce
these data or use themwithin analyses.However, if more than 50%
of data in one arm of a study were lost, but the total loss was less
than 50%, we would have addressed this within the ’Summary of
findings’ table by downgrading quality. We would also downgrade
quality if the loss was 25% to 50% in total.
2. Binary
In the case where attrition for a binary outcome was between 0%
and 50% and where these data were not clearly described, we
would have presented data on a ’once-randomised-always-analyse’
basis (an intention-to-treat analysis (ITT)). Participants leaving
the study early were all assumed to have the same rates of negative
outcome as those who completed. We would have used the rate of
thosewho stayed in the study, in that particular armof the trial, and
apply this also to those who did not. We would have undertaken a
sensitivity analysis testing how prone the primary outcomes were
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to change when data only from people who completed the study
to that point were compared to the ITT analysis using the above
assumptions.
3. Continuous
3.1. Attrition
In cases where attrition for a continuous outcome was between
0% and 50%, and data from only participants who completed
the study to that point were reported, we would have reproduced
these.
3.2. Standard deviations
If the SDs were not reported, we would have tried to obtain the
missing values from the authors. If this was not possible, where
there were missing measures of variance for continuous data, but
an exact standard error and CIs were available for group means,
and either P value or t value was available for differences in mean,
we would have calculated them according to the rules described
in the Cochrane Handbook for Systematic Reviews of Interventions
(Deeks 2011). When only the standard error was reported, we
would have calculated SDs by using the formula SD = SE × square
root (n). The Cochrane Handbook for Systematic Reviews of Inter-
ventions presents detailed formulae for estimating SDs from P val-
ues, t or F values, CIs, ranges or other statistics (Deeks 2011). If
these formulae did not apply, we would have calculated the SDs
according to a validated imputation method that was based on
the SDs of the other included studies (Furukawa 2006). Although
some of these imputation strategies can introduce error, the al-
ternative would be to exclude a given study’s outcome and thus
to lose information. Nevertheless, we would have examined the
validity of the imputations in a sensitivity analysis excluding im-
puted values.
3.3. Assumptions about participants who left the trials early
or were lost to follow-up
Various methods are available to account for participants who left
the trials early or were lost to follow-up. Some trials present only
the results of study completed, while other trials use themethod of
last observation carried forward (LOCF). More recently, methods
such as multiple imputation or mixed-effects models for repeated
measurements (MMRM)have become a standard.While the latter
methods seem somewhat better than LOCF (Leon 2006), we feel
that a higher percentage of participants leaving the studies early
and differences in the reasons for leaving the studies early between
groups are often the core problem in randomised schizophrenia
trials, and therefore would not exclude studies based on the statis-
tical approach used. However, we would have preferred the use of
more sophisticated approaches, for example MMRM or multiple-
imputation over LOCF, and we would have only presented com-
pleter analyses if no ITT data were available. Moreover, we would
have addressed this issue in the item ’incomplete outcome data’ of
the ’Risk of bias’ tool.
Assessment of heterogeneity
1. Clinical heterogeneity
Weplanned to consider all included studies initially without seeing
comparison data to judge clinical heterogeneity. We would have
simply inspected all studies for clearly outlying participants or
situations that we had not predicted. We would have discussed
fully such situations or participant groups.
2. Methodological heterogeneity
We planned to consider all included studies initially without see-
ing comparison data to judge methodological heterogeneity. We
would have simply inspected all studies for clearly outlying meth-
ods that we had not predicted and discussed such methodological
outliers.
3. Statistical heterogeneity
3.1. Visual inspection
We planned to visually inspect graphs to investigate the possibility
of statistical heterogeneity.
3.2. Employing the I2 statistic
We planned to investigate heterogeneity between studies by con-
sidering the I2 method alongside the Chi2 P value. The I2 statistic
provides an estimate of the percentage of inconsistency thought to
be due to chance (Higgins 2003). The importance of the observed
value of the I2 statistic depends on the magnitude and direction
of the effects and the strength of evidence for heterogeneity (e.g.
P value from the Chi2 test or a CI for the I2 statistic). Values of
0% to 40% might not be important; 30% to 60% may represent
moderate heterogeneity; 50% to 90% may represent substantial
heterogeneity and 75% to 100% represents considerable hetero-
geneity (Deeks 2011).
Assessment of reporting biases
1. Protocol versus full study
Reporting biases arise when the dissemination of research findings
is influenced by the nature and direction of the results. These are
described in Section 10.1 of the Cochrane Handbook for Systematic
Reviews of Interventions (Sterne 2011). We would have tried to
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locate protocols of included RCTs. If the protocol was available,
we would have compared the outcomes in the protocol and those
in the published report. If the protocol was not available, wewould
have compared the outcomes listed in the methods section of the
trial report with actually reported results.
2. Funnel plot
Reporting biases arise when the dissemination of research find-
ings is influenced by the nature and direction of the results (Egger
1997). These are described in Chapter 10 of the Cochrane Hand-
book for Systematic Reviews of Interventions (Sterne 2011). We are
aware that funnel plots may be useful in investigating reporting
biases, but are of limited power to detect small-study effects. We
decided not to use funnel plots for outcomes where there were 10
or fewer studies, or where all studies were of a similar size. In other
cases, where funnel plots were possible, we would have sought sta-
tistical advice in their interpretation.
Data synthesis
We understand that there is no closed argument for preference
for the use of fixed-effect or random-effects models. The random-
effects method incorporates an assumption that the different stud-
ies are estimating different, yet related, intervention effects. This
often seems to be true to us, and the random-effects model takes
into account differences between studies even if there is no statisti-
cally significant heterogeneity. However, there is a disadvantage to
the random-effects model. It puts added weight on small studies,
which often are the most biased ones. Depending on the direction
of effect, these studies can either inflate or deflate the effect size.
We planned to use the random-effects model for all analyses.
Subgroup analysis and investigation of heterogeneity
1. Subgroup analyses
1.1. Primary outcomes
We did not plan any subgroup analysis.
1.2. Clinical state, stage or problem
We proposed to undertake this review and to provide an overview
of the effects of information strategies to share the diagnosis of
schizophrenia in general. In addition, we planned to report data
on subgroups of people in the same clinical state, stage and with
similar problems.
2. Investigation of heterogeneity
If inconsistency was high, we would have reported this. First, we
would have investigated whether the data had been entered cor-
rectly. Second, if data were correct, we would have visually in-
spected the graph and successively removed outlier studies to see
if homogeneity was restored. We decided that should this have
occurred with data contributing to the summary finding of no
more than around 10% of the total weighting, data would have
been presented. If not, we would have not pooled data and would
have discussed issues. We know of no supporting research for this
10% cutoff, but are investigating the use of prediction intervals as
an alternative to this unsatisfactory state.
When unanticipated clinical or methodological heterogeneity was
obvious, we would have simply stated hypotheses regarding these
for future reviews or versions of this review. We did not anticipate
undertaking analyses relating to these.
Sensitivity analysis
1. Implication of randomisation
We aimed to include trials in a sensitivity analysis if they were
described in such away as to imply randomisation. For the primary
outcomes, if inclusion of data from these trials did not result in a
substantive difference, they would have remained in the analyses.
If their inclusion did result in important clinically significant but
not necessarily statistically significant differences, we would not
have added the data from these lower-quality studies to the results
of the better-quality trials, but would have presented such data
within a subcategory.
2. Assumptions for lost binary data
Where we had to make assumptions regarding participants lost to
follow-up (see Dealing with missing data), we would have com-
pared the findings of the primary outcomes when we used our
assumptions and when we used data only from participants who
complete the study to that point. If there was a substantial dif-
ference, we would have reported results and discussed them but
would have continued to employ our assumption.
Where we had to make assumptions regarding missing SDs (see
Dealing with missing data), we would have compared the findings
of the primary outcomes whenwe used our assumptions and when
we used data only from participants who completed the study to
that point. We planned to undertake a sensitivity analysis, testing
how prone results were to change when completer-only data were
compared to the imputed data using the above assumption. If there
was a substantial difference, we would have reported and discuss
it but would have continued to employ our assumption.
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3. Risk of bias
For the primary outcomes, we planned to analyse the effects of
excluding trials that were judged at high risk of bias across one
or more of the domains of randomisation (implied as randomised
with no further details available, allocation concealment, blinding
and outcome reporting). If excluding trials at high risk of bias did
not substantially alter the direction of effect or the precision of
the effect estimates, then we would have included data from these
trials in the analysis.
4. Imputed values
For the primary outcomes, we also planned to undertake a sen-
sitivity analysis to assess the effects of including data from trials
where we used imputed values for the ICC in calculating the de-
sign effect in cluster randomised trials.
5. Fixed-effect and random-effects models
We planned to synthesise all data using a random-effects model;
however, we would have also synthesised data for the primary out-
comes using a fixed-effect model to evaluate whether this altered
the significance of the results.
R E S U L T S
Description of studies
We found no studies that met our inclusion criteria.
Results of the search
We identified 44 records through database searches.No additional
records were identified through other sources. We screened these
44 records. Seven records referring to seven studies appeared to be
relevant but were excluded after further inspection. See Figure 1.
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Figure 1. Flow diagram trial selection from search results.
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Included studies
We found no studies that met our inclusion criteria.
Excluded studies
The search found seven potential RCTs (Arvidsson 2014;
Haggarty 2008; Hamann 2006; Sousa 2013; Van Os 2004;
Weisman 2014; Wirshing 2005). None of these seven trials as-
sessed the effectiveness of a communication strategy or any other
intervention to discuss the diagnosis of schizophrenia and we ex-
cluded them.
The excluded studies tested a variety of interventions, mostly com-
munication skills post diagnosis. Arvidsson 2014 andVanOs2004
evaluated a two-way Communication Checklist (2-COM) as a
communication tool to provide an opportunity for patients to
voice their needs and problem to minimise the discrepancy and
miscommunication between patient and professional carer. None
of these communication tools aimed to address the communica-
tion of the diagnosis. Hamann 2006 and Haggarty 2008 investi-
gated a decision aid to facilitate shared decision making for inpa-
tients. Wirshing 2005 evaluated a videotape intervention to en-
hance the informed consent process for research. Sousa 2013 de-
scribed an RCT of a collaborative intervention to promote recov-
ery.Weisman 2014 conducted an RCT to test efficacy of a family-
focused culturally adapted therapy for schizophrenia.
These trials may be relevant for a systematic review on shared
decision making or strategies to enhance communication between
patients and professionals.
Risk of bias in included studies
We found no studies that met our inclusion criteria.
Effects of interventions
See: Summary of findings for the main comparison Different
communication strategies versus treatment as usual
We found no studies that met our inclusion criteria.
D I S C U S S I O N
For this review, we defined the intervention as any communication
strategy or model used specifically for initial sharing of informa-
tion about the diagnosis of schizophrenia or related disorders. We
hypothesised that such a communication strategy would help the
clinician to inform the patient about the nature of the condition
in a manner that would help patients and their carers process the
information, which would lead to better outcomes.
Summary of main results
We found no studies that compared an intervention to commu-
nicate the diagnosis of schizophrenia to patients and their carers
with treatment as usual. We primarily searched intervention stud-
ies but also reviewed other relevant literature, which showed that
delivery of diagnosis to psychiatric patients is not researched well
(Cleary 2009).
Overall completeness and applicability of
evidence
Currently, there is no randomised controlled evidence. It is un-
likely that we have missed any RCTs in view of the comprehensive
literature search strategy. The lack of studies means that, presently,
there is no evidence fromRCTs to guide practice and psychiatrists.
Quality of the evidence
We found no studies that met our inclusion criteria.
Potential biases in the review process
There are few potential biases in the review process. The search
for trials was thorough with no language, date, document type
or publication status limitations and it is unlikely it missed any
studies; however, publication bias cannot be entirely ruled out as
a possible bias.
Agreements and disagreements with other
studies or reviews
In view of the lack of studies, co-comparisons were difficult. One
review of the literature also found no communication strategies
available for diagnosis of schizophrenia and suggested that the
SPIKES (S: setting up; P: assessing the patient’s perception; I: ob-
taining the patient’s invitation; K: giving knowledge and infor-
mation to the patient; E: addressing the patient’s emotions with
empathic responses; S: strategy and summary) model could be ap-
plied to schizophrenia (Seeman 2010). However, this was a qual-
itative review of the literature, and as in our review, no evidence
from RCTs was available.
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We found studies that discussed the general communication needs
of patients and how these could bemetwith communication needs
related to the information about medication, adverse effects of
medication, problems experienced by carers and their communi-
cation needs. However, none of the studies examined the commu-
nication needs specific to delivery of diagnosis (Dott 2001; Priebe
2007).
Some non-randomised studies suggested that a substitute diagno-
sis in place of a schizophrenia diagnosis is often provided (Luderer
1993; McDonald-Scott 1992), even when the service users asked
for exact diagnosis (McDonald-Scott 1992). There is still, today,
a general lack of guidance on how the news about the diagnosis
of schizophrenia is communicated to patients and their carers. In
one qualitative study from Australia, carers described the “long
and difficult pathway” to being given a diagnosis and haphazard
means of finding a diagnosis (Outram 2015). This may be due to
a number of challenges related to the nomenclature, uncertainties
surrounding the diagnosis of schizophrenia, its variable outcome
and the stigma associated with having a serious mental illness.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
1. For people with schizophrenia
Currently there is no evidence from randomised controlled trials
(RCTs) on how disclosure of diagnosis is best done for schizophre-
nia.However, service users should be encouraged to ask basic ques-
tions about the diagnosis and how this was reached.
2. For clinicians
Clinicians need to be aware of the lack of evidence-base in this
area and there is a need for further research. For now, developing
skills based on best practice in the communication of bad news
in other branches of medicine or in other psychiatric conditions
such as dementia or learning disability is the only available option.
However, in view of the unique nature of schizophrenia consider-
able modifications would be needed.
3. For funders and managers
National Institute for Health and Care Excellence guidelines rec-
ommend that the information about both the causes and treat-
ment options for schizophrenia are discussed with the patients and
carers. However, there is little guidance, if any, on how the diag-
nosis is delivered (NICE 2009).
There is a need to evaluate how current practice affects patients,
how much they want to know and the impact of disclosure of
the diagnosis. Limited literature suggests that the communication
priorities of service users and providers differ considerably and this
communication gap can have serious implications and the source
of distress for service users (McCabe 2008). In most high-income
countries people with first episode psychosis are under the care of
Early Intervention in Psychosis services and are likely to receive
the diagnosis of schizophrenia from these services so the managers
and commissioners for these services need to be aware of the lack
of evidence base in relation to the delivery of diagnosis. There is
an urgent need to fund the studies which explore this specific area.
Implications for research
1. General
There is an enormous gap in the knowledge in this area. As de-
scribed above, some studies suggest that almost half of service
users with schizophrenia had not received any detailed informa-
tion about their diagnosis, and the practice of psychiatrists varied
considerably. The anecdotal evidence seems to suggest that people
with schizophrenia ’learn’ the diagnosis, as they ’experience’ the
psychiatric services (Farooq 2015). RCTs are needed to evaluate
the effectiveness of models which help the clinicians to deliver di-
agnosis.
Further research is needed to develop models for communicating
the diagnosis of schizophrenia. Research to understand the per-
ception and communication needs of people with schizophrenia
will help to develop the theoretical underpinning for the relevant
interventions in this area. It should be possible, for example, to
design a communication checklist which will help to complete of
all the necessary steps in sharing the information about the diag-
nosis of schizophrenia. Such communication checklists have been
developed and evaluated in RCTS to help communication post
diagnosis (Dott 2001; van Os 2004).
2. Specific
Therefore, three priority areas for research in this area are identi-
fied.
1. To understand the views and experiences of people with
schizophrenia, carers and clinicians receiving and giving
information related to diagnosis treatment options and prognosis
of schizophrenia.
2. To design interventions that improve the communication
skills of mental health professionals to share the information
about the diagnosis treatment options and prognosis of
schizophrenia.
3. To evaluate these interventions in RCTs.
The literature on communication skills training for other serious
illnesses such as cancer can provide some insights into designing
the trials in this area (Moore 2013). First, there is need to develop
core study outcomes, both for clinicians and patients that can
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be used in these trials. Second, the validated scales to measure
the communication skills of clinicians in communicating the bad
news will need to be developed. A common technique used in
the literature in oncology is to use simulated patients for assessing
the effectiveness of communication skills training, which will be
helpful in the field of schizophrenia, as there is no experience at
present in structured patient communicationwith patients to share
the bad news about the diagnosis of the illness. A possible design
for future trial is described. It must be noted that any trial in the
present state of knowledge will be exploratory in nature, which
will help to inform the suitable outcome measures, the scale to
measure these outcomes and possible power calculations. See also
Table 1 and Table 2.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Arvidsson 2014 Allocation: cluster randomised controlled trial.
Participants: people with schizophrenia or schizoaffective syndromes
Intervention: communication tool to enhance the sense of empowerment, satisfactionwith care, therapeutic alliance
and unmet needs post diagnosis
Reason for exclusion: not specifically interventions regarding the delivery of diagnosis of schizophrenia
Haggarty 2008 Allocation: cluster randomised controlled trial.
Participants: people with schizophrenia and related disorders
Intervention: a shared care model of Transition into Primary care Psychiatry
Reason for exclusion: not specifically interventions regarding the delivery of diagnosis of schizophrenia
Hamann 2006 Allocation: randomised controlled trial.
Participants: inpatients with schizophrenia.
Intervention: shared decision-making programme post diagnosis
Reason for exclusion: not specifically interventions regarding the delivery of diagnosis of schizophrenia
Sousa 2013 Allocation: randomised controlled trial.
Participants: people with psychotic disorders (schizophrenia, bipolar and depression with psychotic features)
Intervention: levels of recovery from Psychotic Disorders Scale enabled dialogue to reduce discrepancy between
patient and clinician in assessing symptoms, adherence and functionality post diagnosis
Reason for exclusion: not specifically interventions regarding the delivery of diagnosis of schizophrenia
Van Os 2004 Allocation: randomised controlled trial.
Participants: schizophrenia.
Intervention: a 2-way communication checklist as a clinical intervention to improve communication between
patients and the professionals post diagnosis
Reason for exclusion: not specifically interventions regarding the delivery of diagnosis of schizophrenia
Weisman 2014 Allocation: randomised controlled trial.
Participants: people with schizophrenia and related disorders
Intervention: family-focused, culturally informed therapy.
Reason for exclusion: not specifically interventions regarding the delivery of diagnosis of schizophrenia
Wirshing 2005 Allocation: randomised controlled trial.
Participants: people with schizophrenia.
Intervention: a videotape intervention to enhance the informed consent process for medical and psychiatric treat-
ment research
Reason for exclusion: not specifically interventions regarding the delivery of diagnosis of schizophrenia
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. Suggested future trial
Methods Procedure Comments
Randomisation and
allocation
Randomisation using computer-generated
numbers.
Allocation using sealed envelopes.
It may not be possible to have a double-blind
design in these trials. It will be important that
the assessors of the outcome measures are blind
to the allocation of participants
Participants Resident psychiatrists who have been in train-
ing for at least 3 years and treating patients who
are willing to participate in the communication
skill trainingprogramme aimed at disclosing the
diagnosis of schizophrenia and its assessment
procedure. They will be randomised to an in-
tervention and a waiting list control
-
Interventions Intervention: a communication strategy to dis-
close the diagnosis and outcome of schizophre-
nia consisting of a standard training pro-
gramme. The training programme would con-
sist of 1. standard content regarding knowledge
about the diagnosis of schizophrenia, nature of
illness and possible outcomes and 2. necessary
communication skills to deliver the bad news
The training package will be delivered using the
following teaching methodologies:
1. 1-hour theoretical session;
2. role play of predefined cases in sharing
information about diagnosis and outcome of
schizophrenia and detailed feedback about the
performance in role play;
3. small groups discussion (maximum 5 partici-
pants) about the practical problems in commu-
nicating with patients and stress management
techniques to overcome the emotional distress
when sharing the bad news
Control: a group of resident psychiatrists on
waiting list.
The training methods vary immensely in the
present literature on communicating bad news.
This may consist of face-to-face individual or
group training sessions. The training will de-
pend upon the guidance developed in sharing
information about the diagnosis and outcome
and underlying theoretical framework
Outcome measures Physicians in each group will communicate
the news about the diagnosis and outcome of
schizophrenia for a standardised patient (SP)
encounter. The skills of trainee psychiatrists in
both groups will be analysed using the records
We suggest the scoring for communication skills
rated on the video-taped interviews. They can
also be rated ’live’ when the actual interview
is taking place. Simulated patient consultations
are routinely used in assessing the interviewing
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Table 1. Suggested future trial (Continued)
of the patient encounter recorded earlier. Out-
come measures will consist of scores by inde-
pendent assessor and the report of SP involved
in the interview. The assessors will be blind to
the status of trainees, as to which group they
belong. Each encounter will be recorded using
a predetermined scoring sheet on the following
aspects
1. Understanding the nature of illness and its
outcome, defined by SP
2. Satisfaction with interview as reported by as-
sessor and SP
3. Communication skills of the resident psy-
chiatrists using the content analysis, verbal and
non-verbal communications checklist
4. Any distressing experience by the SP.
and communication skills and are useful in pro-
viding the insight initially. After initial studies,
real patients could be recruited
Table 2. Comparisons relevant to other reviews suggested by excluded studies
Intervention Control Participants Reference tag Potential Cochrane ti-
tle
Communication check-
list
Psychoeducation or
treatment as usual
People
recently diagnosed with
schizophrenia based on a
standard diagnostic cri-
teria or carers, or both
Arvidsson 2014; Van Os
2004
Communication check-
lists for discussing the
diagnosis, treatment op-
tions and prognosis of
schizophrenia
Shared decision making Treatment as usual or
psychoeducation
People
recently diagnosed with
schizophrenia based on a
standard diagnostic cri-
teria or carers, or both
Hamann 2006 Shared decision making
for treatment planning
in schizophrenia and re-
lated disorders
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We have expanded the background substantially to clarify our intervention in that delivery of diagnosis not only involves revealing
the diagnosis but also involves communication regarding treatment options and prognosis for the patient. We wanted to distinguish
this from general communication between clinicians and patients during treatment, which is the focus of another Cochrane review
(Papageorgiou 2017).
We have extended the age of participants to greater than 16 years, as the age of onset of schizophrenia, particularly for males, and
therefore when diagnosis is most likely to be given is late adolescence, early adulthood. This expansion and clarification of the definition
did not change our inclusion criteria or objectives of the original protocol. We have also expanded our ’Why it is important to do this
review’ section. We have reordered and reworded the outcomes to help categorise data collection into continuous or binary but not
changed the type of outcomes required. We have specified that all ’Summary of findings’ table outcomes should be clinically important.
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